Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

This expert-led session offers oncology professionals a comprehensive overview of MZL subtypes, traditional treatment pathways, and the promising role of targeted oral therapies—specifically BTK inhibitors such as zanubrutinib.

Topics covered include:

• The unique characteristics and prognosis of the three MZL subtypes: MALT lymphoma, nodal MZL, and splenic MZL
• The evolving role of targeted therapies in treating relapsed or refractory MZL
• Clinical data and outcomes from the MAGNOLIA study on zanubrutinib
• Detailed information on dosing strategies, safety profile, and patient management considerations
• Guidance on managing drug interactions, side effects, and special patient populations

View Prescribing Information